Ipratropium bromide dry-powder inhalation - Dura/Spiros

Drug Profile

Ipratropium bromide dry-powder inhalation - Dura/Spiros

Alternative Names: Ipratropium bromide Spiros; SCH 1000 dry-powder inhalation - Dura/Spiros

Latest Information Update: 07 Jul 2000

Price : $50

At a glance

  • Originator Dura Pharmaceuticals; Spiros Development Corporation II
  • Class Antiasthmatics; Antibronchitics; Atropine derivatives; Bronchodilators; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 07 Jul 2000 New profile
  • 07 Jul 2000 Discontinued-Unspecified Phase in Chronic obstructive pulmonary disease in USA (Inhalation)
  • 07 Jul 2000 Discontinued-Unspecified Phase in Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top